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Abstract A large number of  literature and study that are published discuss about the correlation 
between the use of antiretroviral (ARV) with insulin resistance, especially protease inhibitors. 
This study’s objective is to assess the correlation between duration of administration of protease 
inhibitors and insulin resistance in HIV-patients. An observational research was conducted in 
Polyclinic of Special Service Center (Posyansus) for HIV patients at  H. Adam Malik General 
Hospital from August - December 2019, and the data was analysed using Chi-Square test. The 
subjects were 34 HIV-patients treated with protease inhibitor. The average age of the subjects 
range from 34 - 49 years (54.3%), men (71.4%) and women (28.6%). Most of the subjects use 
ARV drugs from 6-12 months (60%). In which 13 people (37.1%) has insulin resistance. The 
average HOMA-IR value was 2 (0.8-16.5), fasting blood sugar levels were 86 (70-283) mg / dl, 
fasting insulin levels were 9.1 (4.1-79.4) (µU / ml)., urea levels of 20.88 ± 9.7 mg / dl and 
creatinine levels of 0.81 ± 0.15 mg / dl. There was a significant correlation between the duration 
of ARV treatment with insulin resistance. The prolonged use of Protease Inhibitors will further 
increase insulin resistance. 
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Abstrak. Banyak literatur dan penelitian yang membahas mengenai hubungan penggunaan ARV 
dengan resistensi insulin, khususnya protease inhibitor. Penelitian ini bertujuan untuk 
mengetahui hubungan lama pemberian protease inhibitor dengan resistensi insulin pada pasien 
dengan HIV. Penelitian observasional dengan desain studi cross sectional, dengan analisis 
statistic menggunakan uji chi-square. Penelitian dilakukan di Poliklinik Pusat Pelayanan 
Khusus (Pusyansus) RSUP H. Adam Malik bulan Agustus – Desember 2019. Sampel penelitian 
berasal dari pasien HIV yang mendapat terapi ARV jenis protease inhibitor sebanyak 34 orang. 
Karakteristik subjek penelitian memiliki rentang usia terbanyak pada usia 34 – 49 tahun yaitu 
sebanyak 19 orang (54,3%), laki-laki sebanyak 25 orang (71,4%) dan perempuan sebanyak 10 
orang (28,6%). Lama pemakaian obat ARV paling banyak pada kelompok 6-12 bulan yaitu 
sebanyak 22 orang (60%). Resistensi insulin pada penelitian ini sebanyak 13 orang (37,1%). 
Nilai median  HOMA-IR subjek penelitian sebesar 2 (0,8-16,5), gula darah puasa (GDP):  
86(70-283) mg/dl, kadar insulin puasa:  9,1 (4,1-79,4) (µU/ml), kadar ureum:  20,88 ± 9,7 mg/dl 
dan kadar kreatinin 0,81 ± 0,15 mg/dl. Terdapat hubungan yang signifikan antara lama 
pengobatan ARV dengan resistensi insulin.. Semakin lama penggunaan Protease Inhibitor akan 
semakin meningkatkan resistensi insulin. 
 
Kata Kunci: HIV, Protease inhibitor, Resistensi Insulin 
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1 Introduction 
Human Immunodeficiency Virus (HIV) is one of the diseases that has continued to grow 
from year to year. World Health Organization (WHO) and UNAIDS reported there was 39.5 
million people has been diagnosed with HIV across the world and about 2 million people in 
Latin America [1]-[2]. 
A large numbers of literature and study that are published discuss about the correlation 
between using antiretroviral (ARV) with insulin resistance, however only a few that discuss 
about the correlation in HIV patient, regarding the activity of ARV in process of insulin 
resistance. In vitro study show the use of Protease Inhibitor (PI), include ritonavir, may acutely 
cause the inhibition activity of glucose transporter-4 (GLUT-4) that can cause insulin resistance 
in normal patient and HIV-positive patients that have lipodystrophy [3]-[4]. 
Insulin resistance found in 21% HIV patients who in on going ARV treatment. In vitro 
study and single drug research on healthy patient dan infected with HIV has proven that IR may 
induced by ARV [5]. 
Few studies report that the cause of insulin resistance in number HIV patients is PI 
(protease inhibitor). This can be explained by three assumption: in the plasma membrane the 
activity of GLUT-1 and GLUT-4 were restricted, inhibition from differentiation of pre 
adipocyte/adipocyte, and induced apoptosis in adipose tissue. Research by Murata and Hruz et 
al in [6], suggest that the inhibition of GLUT-4 was the primary mechanism accountable in an 
induced insulin resistance. 
Few studies analyzed correlation between insulin resistance with use of ARV, especially 
PI-type in HIV-positive patients. Koster et al in [7] found that PI in therapeutic dose was 
enough to induced insulin resistance and beta pancreas cell damage in mice. This study used 
indinavir as ARV and the method to look insulin resistance that used is hyperglycaemic clamps. 
Gullein et al in [2], stated there was a correlation between use of ARV and insulin resistance. In 
that study, insulin resistance prevalence is 34%, two times higher than patient without HIV. The 
research of metabolic evaluation in treatment-naives assesing the impact of two boosted PI on 
lipids and other markers, a randomized study using 4 phase that was conducted by Overton et al 
in [8], compared the metabolic adverse effect of darunavir/ritonavir with atazanavir/ritonavir 
using hyperinsulinemic euglycemic clamp methods. That research concluded that after 48 weeks 
of consuming the combination of darunavir/ritonavir with atazanavir/ritonavir, the drugs has no 
significant effect to insulin resistance. [8]-[9] 
Research about the duration of ARV treatment especially relate to monitoring the 
occurrence of side effects of insulin resistance has a different duration. Noor et al in [10] report 
that administration of LPV/r (lopinavir/ritonavir) for 5 days can induced insulin resistance, 
however in this study the effect of LPV/r were not analysed in longer duration. According to 
Permenkes in [11] reported on the use of ARV has a different variation of time to the showing 
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signs of toxicity. Abnormalities that appear related to metabolic such as insulin resistance are 
begin to occur on ARV use for 6-18 months. 
The difference on few result researches regarding the effects of PI in insulin resistance in 
HIV patients attract the attention of researchers to re-examine the correlation between the 
administration of PI to insulin resistance in HIV patients. Compared to some previous research, 
this is the first research that focuses to investigate the correlation between the duration of ARV 
with the incidence of insulin resistance in HIV patients, particularly in Medan. 
2 Methods 
This research is an observational research using a cross sectional design and is analysed 
using Chi-Square test. The study was conducted in a special service center for HIV patients in 
H. Adam Malik General Hospital from August to December 2019. Every patient that came to 
the clinic who had been diagnosed with HIV and receiving therapy using ARV that contain PI 
was given a questionnaire. This study had several inclusion criterias that consist of : HIV 
patients who had received therapy using PI, patients that have been treated for longer than 6 
months, and patient who were 18 above in age. All of the patients was tested for fasting blood 
glucose, and using fasting insulin levels to establish signs of insulin resistance. Blood glucose 
levels were examined using the glucose oxidase method, hyperglycemia was considered if 
fasting blood glucose level ≥100 mg / dL. Insulin testing was carried out using 
chemiluminescent (sandwich) immunoassay with substance such as serum/ plasma Li-heparin / 
plasma K3-EDTA / plasma sodium citrate. The presence of insulin resistance was determined 
using mathematical model of Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) 
with the formula [Fasting insulin levels [μU / ml × fasting blood glucose (mmol /L) / 22,5)]. 
The author defined insulin resistance as HOMA-IR level is ≥ 2.6 [12]. Period of treatment using 
PI was the independent variable of this research, while the dependent variable is insulin 
resistance.  
3 Result dan Analysis 
3.1 Subjects Characteristic 
This research involves 35 research subject which have fulfilled the inclusion criteria. From 
the total of 35 subject. there were 10 females (28,6 %), and 25 males (71.4%). With the median 
age of 38,85 years. the average age of the subject range from 34-49 years is 19 subjects 
(54,3%). The same results were found in research that was conducted by Mulyati et al in [14] 
who reported that more males (67%) have HIV instead of females (33%) with an overall age 
average of 3.7 1 ± 10.7 years. Araujo et al in [13], also reported the same results in which 75% 
of men that have HIV were in the age range of 39-49 years old. A research shows that infection 
of HIV occurred more frequent in younger age range from 12-35 years, this result is probable 
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due to the fact that a lot of younger people do not use protection while engaging in sexual 
intercourse. Protection in this context is using a condom, frequent changes in partners and drugs 
abuse or consumed alcohol [15]. 
The mean Body Mass Index (BMI) of subject is 24. 35 ± 3.99 kg/m2, and as much as 13 
(37,1%) were categorized as normoweight. The mean systolic pressure is 110 (100-130) mm Hg 
and the diastolic pressure is 70 (60-90) mm Hg. From these results it can be concluded that the 
average BMI is overweight but the highest percentage is normoweight while for the blood 
pressure is still within normal limits. This result concedes by the study that was conducted by 
Araujo et al in [13] who reported that the mean BMI of HIV patients receiving ARV was 
23.9kg/m2 
The mean results HOMA-IR value of the research subject was 2 (0.8-16.5). The subjects 
who experienced insulin resistance in this study were 13 people (37.1%). The prevalence of this 
results is slightly higher than previous studies conducted by Gullein et al in [2] who reported the 
prevalence of insulin resistance of 34%, twice as high as in a population of patients without HIV 
with a HOMA-IR value of ≥ 2.1. In line with this, Salazar et al in [16] reported HOMA-IR 
values> 2 related to insulin resistance. 
The subject that use of PI-type of ARV drugs in this study mostly ranged between 6-12 
months, as many as 22 people (60%). Research on the use of antiretroviral drugs, especially 
related to monitoring the occurrence of side effects of insulin resistance has a different duration. 
Noor et al in [10] reported that the administration of LPV / r (lopinavir / ritonavir) for 5 days 
could induce insulin resistance, but in this study the effect of LPV / r were not assessed in the 
longer term. The research that was conducted by Dirajral-Fargo et al in [17] found that insulin 
resistance marked by an increase in HOMA-IR from basic value appeared at 4 weeks after 
administration of atazanavir/ritonavir (ATV/r) and tenofovir/emtricitabine (TDF/FTC) 
raltegravir (RAL), or darunavir/ritonavir (DRV/ r) 
The mean duration of subject using ARV drugs specifically PI- type, range between 6 to 12 
months, is 22 people (60%). Some research that study the duration of using ARV drugs with the 
long-term side effects of insulin resistance have different durations. Noor et al [10] reported that 
the administration of LPV / r (lopinavi / ritonavir) for 5 days could induce insulin resistance, but 
in this study the effect of LPV / r was not assessed in the longer term. Meanwhile, Dirajral-
Fargo et al [17] study discover that insulin resistance that was marked by an increase in HOMA-
IR from baseline appeared at 4 weeks after administration of tenofovir/emtricitabine (TDF / 
FTC) plus atazanavir/ritonavir (ATV / r), darunavir/ritonavir (DRV / r), or raltegravir (RAL). 
The mean fasting blood glucose of the subjects was 86 (70-283) mg/dl and levels of fasting 
insulin of the subjects was 9,1 (4,1-79,4) (µU/ml). Previous research have a slight difference 
results from this study whereas patients who received ARV drugs was 96.4 (88–103) mg/dl with 
fasting insulin levels of 12.8 (3.2–14.8) µU / ml [13]. However, both blood glucose levels and 
fasting insulin levels from either study was still within normal value. According to Perkeni 2015 
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in [18] states that the normal value of fasting blood glucose were <100mg/dl, while Rajos et al 
in [19] recommends normal fasting insulin levels when the levels are < 13 µU/ml. 
The mean ureum levels in subject of this research was 20.88 ± 9.7 mg/dl. While the mean 
creatinine levels were 0.81 ± 0.15 mg/dl. Therefore it can concluded that all of the subjects renal 
function is still normal, in spite of the use of ARV drugs for 6-12 months. This results 
correspondence with the previous research that was conducted by Budiman in [20] who reported 
that HIV patients that received ARV had an average ureum level of 19.95 ± 9.56 mg / dl and a 
mean creatinine level of 0.82 ± 0.19 mg / dl [20]. Data that shows of the characteristics of 
subjects in this study presented in table 1 below. 
Table 1 The Subjects Characteristics* 
Subjects Characteristic Mean  n (%) 
 
Age. (year) 38.85± 9.7  
Gender 
 Male 
 Female 
 
Body Mass Index (kg/m2) 
 
 
 
 
24.35 ± 3.9 
 
 
25 (71.4) 
10 (28.6) 
 
 
Blood Pressure (mm Hg) 
SBP  
DBP  
 
110.57 ± 10.2 
74.57 ±  7.4 
 
 
 
HOMA IR 
 With Insulin Resistance 
 Without Insulin Resistance 
 
3.64 ± 4.4 
7.44 ± 5.4 
1.40 ± 0.4 
 
 
Fasting Blood Glucose (mg/dl) 
Fasting Insulin (µU/ml) 
Ureum (mg/dl) 
Creatinine (mg/dl) 
96.6 ± 36.8 
14.77 ± 17.4 
20.88 ± 5.7 
0.81 ± 0,15 
 
HOMA-IR:Homeostatic Model Assessment for Insulin Resistance; SBP, Systolic Blood Pressure;  
DBP, Diastolic Blood Pressure 
*All data is presented as mean ±SD and n (%) for gender    
 
3.2 Comparison of Renal Function Test According to The Duration of Treatment 
Comparison of the mean ureum and creatinine levels based on the duration of 
treatment presented that there were no significant differences in the levels of ureum and 
creatinine in the two groups of treatment, respectively (p = 0.226; p = 0.168). For the 
complete data on urea and creatinine levels and the comparison of the two based on the 
length of treatment for this type of PI ARV research is presented in Table 2 below.  
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Table 2 Comparison of Renal Function Based on Duration of Treatment 
Variable 6-12 months >12 months  p 
Ureum (mg/dl) 19.9 ± 5.71 22.35 ± 5.81 0.226 
Creatinine (mg/dl) 0.75 ± 0.15 0.86 ± 0.13 0,168 
Dependent T-Test for abnormal distribution 
 
Therefore, it can be concluded that the levels of ureum and creatinine in the two 
groups of treatment did not differ significantly and both were still within normal limits. 
These results resemble with the research that was conducted by Yeboah et al in [21]. 
Whom also reported that after 6 months of ARVs there were a slight decrease in GFR 
but the levels of ureum and creatinine were still within normal limits. Yeboah et al in 
[21] also added that there was no difference in glomerular filtration rate (GFR) based on 
the duration of ARV administration. Duration of ARVs in this case is divided into <2 
years and ≥ 2 years. The description of mean levels of ureum and creatinine is presented 
in the graph below 
 
3.3 The Correlation Of Duration Of Treatment With Insulin Resistance 
Tabel 3 The correlation of duration of with insulin resistance 
 
 
Variable 
Insulin Resistance 
n(%) 
 
 
 
P 
 
 
OR 
 
 
IK 95% 
Yes No    
Duration Of Treatment 
 6 – 12 month 
 > 12 months 
 
4 (42.9) 
9 (87.5) 
 
 
17 (57.1) 
5 (12.5) 
 
 
 
0.018* 
 
 
7.65 
 
 
1.63-35.79 
 chi square test; p<0,05 
 
 
Based on table 3. it shows that the subjects of the study with >12 months ARV 
treatment that had insulin resistance was 87.5% while the subjects with 6-12 months 
ARV treatment that had insulin resistance was 49,2%, it can be concluded that the 
subjects with >12 months treatment  have higher percentage compare to the subjects 
with 6-12 months of treatment. Based on chi square analysis results, that were obtained 
there was a significant relation between the duration of ARV treatment with insulin 
resistance 9p=0.018; OR 7.65). It also can be concluded that patient with >12 months of 
ARV treatment has a risk 7.65 times greater than patient with 6-12 months of ARV 
treatment. According to Permenkes in [11], reported that the toxicity of ARV after 6-18 
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months administration can  cause the metabolic abnormality that generally happen by PI 
(protease inhibitor), include hyperlipidemia, accumulation of lipid insulin resistance, 
diabetes and osteopenia [22]. The insulin resistance percentage according to length of 
treatment in this research is presented in the graph below. 
 
Along with Fiesha and Belete in [23] research, also reported there was a relation 
between duration of ARV treatment with incidence of diabetes mellitus (p=0.021; 
OR=2.67). Based on Gullein et al in [2], stated that there was also a relation between the 
use of ARV and insulin resistance. In that study, insulin resistance prevalence was 34%, 
2 times higher than population patient without HIV. Study by Gullein et al in [2] did not 
use control, therefore use a cutoff value HOMA-IR was 2,1 based on previous reasearch 
in Hospital Nacional Cavetano Heredia with similar characteristics ethnics and 
geographics Moreover, other factors that aggravated the relation of insulin resistance 
and usage of ARV was age and BMI. The variety of mechanism in impaired glucose 
metabolism in adult HIV patients was the cause of direct effect from HIV infection, side 
effect of ARV, inflammation and other risk factor of decreased glucose metabolism. 
Side effects of anti-HIV protease inhibitor and NNRTI related with the increasing risk 
of diabetes and insulin resistance. [17]. Some researches also stated that there is a 
correlation between the use of PI with the incidence of lipodystrophy, dyslipidemia and 
insulin resistance. In physiological concentration there is also a distinction of the level 
of metabolic effects of PI [24].  
Some review said the drugs that contain PI, which cause insulin resistance in 
HIV patients can be explained by three assumption:  inhibiton of GLUT-1 and GLUT-4 
in membran plasma, inhibition from differentiation pre adipocyte/adipocyte, and 
induced apoptosis in adipose. Study by Hruz and Murata et al in [6] suggest that main 
mechanism that responsible in induced insulin resitance was inhibition of glucose 
transporter. PI selectively and potentially decrease activity of GLUT-4, without altering 
the signalling mechanism of insulin or translocation of GLUT-4. The GLUT-4 itself 
work to limited the step of glucose elimination, inhibition effect of PI on GLUT-4 cause 
insulin resistance in patients with HIV. Few patients can suffer diabetes as a result from 
beta pancreatic cell failure to compensate this resistance.[6]-[25]-[26] 
In normal muscle and fat tissue, GLUT-4 was recycled in between the cell 
plasma and intracelluler storage. If there is insulin, this balance will change that can 
cause translocation receptor for intracelluler to plasma membrane. The effect is increase 
maximum of glucose transport rate into cell. Translocation GLUT-4 intracelluler induce 
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by insulin, actually starts from binding insulin to receptors in extracelluler part. This 
binding triggers several reactions of phosphorilation which is very important to action 
of insulin. Autophosporilation in tyrosin amino acid that was trigger by insulin and 
happen in cytoplasm domain from receptors will strengthen action of tyrosin kinase 
enzyme, which the phosphorilizes several intracelluler protein including Insulin 
Receptor Substrate-1 (IRS-1). Phosphorillation from IRS-1 results in secondary signals 
that connect the insulin receptor on glucose transport transmembran. Furthermore, the 
activation of phosphatidylinositol 3-kinases is necessary to stimulate glucose transport 
using insulin and needed to induced translocation from GLUT-4 to plasma membrane. 
[27] 
4 Conclusion  
Based on the analysis of the data obtained in this study it can be establish that there is a 
significant correlation between the length of ARV treatment with insulin resistance. The 
prolonged use of Protease Inhibitors will further increase insulin resistance. 
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